Comparative Clinical Outcomes of Transdermal Drug Patches

Abstract

Transdermal drug delivery systems (TDDS) provide controlled, sustained drug release through the skin, offering advantages over oral and injectable routes: avoidance of first-pass hepatic metabolism, steady-state plasma concentrations without peak-trough fluctuations, improved patient compliance through weekly or biweekly application, and non-invasive self-administration. Over 35 transdermal products are approved globally, delivering analgesics (fentanyl, buprenorphine), hormones (oestradiol, testosterone, contraceptives), cardiovascular drugs (nitroglycerin, clonidine), CNS agents (rivastigmine, rotigotine, methylphenidate), and smoking cessation aids (nicotine). Despite widespread use, systematic comparative evaluation of clinical outcomes across transdermal products -- accounting for formulation technology, skin permeation enhancement, adhesion performance, and pharmacokinetic variability -- remains limited. We present the Transdermal Clinical Outcomes Framework (TCOF), evaluating five transdermal technology platforms -- matrix reservoir patches, drug-in-adhesive monoliths, microstructured transdermal systems (microneedles), iontophoretic active delivery, and nanoparticle-enhanced patches -- across four clinical outcome dimensions (therapeutic efficacy, pharmacokinetic consistency, skin tolerability, and patient adherence). Our Transdermal Clinical Outcome Score (TCOS) measures efficacy equivalence to oral/injectable comparators, inter-patient PK variability, local skin reaction rate, wear-time adherence, and patient preference. Microstructured transdermal systems achieve the highest TCOS (0.926) through microporation that bypasses the stratum corneum barrier while maintaining controlled release, while drug-in-adhesive monoliths achieve the highest patient adherence (0.960) through thin, flexible, cosmetically acceptable patch designs